What do dipeptidyl‑peptidase‑4 inhibitors (DPP4i) and sodium‑glucose co‑transporter‑2 inhibitors (SGLT2i) refer to in diabetes management?

DPP4i and SGLT2i: Definitions and Clinical Roles in Diabetes Management

DPP4i stands for dipeptidyl peptidase-4 inhibitors (also called "gliptins"), and SGLT2i stands for sodium-glucose cotransporter-2 inhibitors (also called "gliflozins")—both are oral antidiabetic drug classes with complementary mechanisms that address different pathophysiologic defects in type 2 diabetes. 1

DPP4i (Dipeptidyl Peptidase-4 Inhibitors)

Mechanism and Characteristics:

• DPP4i work by blocking the enzyme that breaks down incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion in a glucose-dependent manner and suppressing glucagon release 1
• These agents lower HbA1c by approximately 0.5-1.0% without causing hypoglycemia when used alone or with metformin 1
• They are weight-neutral and do not require dose adjustment until eGFR falls below 30-45 mL/min/1.73 m² (depending on the specific agent) 1

Available DPP4i include:

• Sitagliptin, saxagliptin, linagliptin, alogliptin (in the United States) 1
• Teneligliptin (in some Asian markets) 2

Key Clinical Advantages:

• Maintain efficacy and tolerability in older adults, even with declining renal function 3
• Low risk of hypoglycemia makes them suitable for patients at high risk of glucose fluctuations 4, 5
• Cardiovascular outcomes trials (SAVOR-TIMI 53, EXAMINE, TECOS) have demonstrated cardiovascular safety, though without significant reduction in major adverse cardiovascular events 5

SGLT2i (Sodium-Glucose Cotransporter-2 Inhibitors)

Mechanism and Characteristics:

• SGLT2i block glucose reabsorption in the proximal renal tubules (specifically the S1 and S2 segments), increasing urinary glucose excretion and lowering blood glucose independently of insulin 1, 6
• They reduce HbA1c by 0.5-1.0%, promote weight loss of 1.5-3.5 kg, and lower systolic blood pressure by 3-5 mmHg 7
• The renal glucose threshold is approximately 180 mg/dL; above this level, SGLT2 transporters become saturated and glucosuria occurs 6

Available SGLT2i include:

• Highly selective for SGLT2: Dapagliflozin, empagliflozin, ertugliflozin 6, 8
• Moderate SGLT1 activity: Canagliflozin (also affects intestinal glucose absorption) 6, 8
• Dual SGLT1/SGLT2 inhibitor: Sotagliflozin 6

Critical Cardiorenal Benefits (Beyond Glucose Lowering):

• Empagliflozin reduces cardiovascular death in adults with type 2 diabetes and established cardiovascular disease 8
• Canagliflozin reduces risk of MI, stroke, CV death, and end-stage kidney disease in patients with diabetic nephropathy 8
• Dapagliflozin reduces hospitalization for heart failure and cardiovascular death in both diabetic and non-diabetic patients with heart failure 8
• These cardiovascular and kidney benefits persist even when glucose-lowering efficacy is lost at lower eGFR levels 1, 6

Renal Function Considerations:

• Glucose-lowering efficacy progressively declines as eGFR falls below 45 mL/min/1.73 m², with substantially reduced glycemic effects below 30 mL/min/1.73 m² 6
• However, cardiorenal protective benefits remain intact across all eGFR categories down to 20 mL/min/1.73 m² 1, 6
• SGLT2i can be initiated in most patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m², and should be continued even when eGFR falls below initiation thresholds unless not tolerated or dialysis is initiated 1

Combination Therapy: DPP4i + SGLT2i

Rationale for Combining Both Classes:

• The two drug classes have complementary mechanisms of action without overlapping toxicities 4, 5
• DPP4i enhance insulin secretion (insulin-dependent), while SGLT2i promote glucose excretion (insulin-independent) 4, 2
• No significant pharmacokinetic drug-drug interactions occur when administered together 2

Clinical Efficacy of Combination:

• Dual therapy provides HbA1c reductions of 1.1-1.5% when added to metformin, superior to either monotherapy 5, 9
• The additional glucose-lowering effect is more pronounced when an SGLT2i is added to a DPP4i than vice versa 2
• At baseline HbA1c <8.0-8.5%, DPP4i provide slightly greater HbA1c lowering than SGLT2i; at HbA1c ≥8.0%, SGLT2i are more effective 3
• For patients with HbA1c ≥8.0%, dual DPP4i-SGLT2i therapy should be considered to achieve glycemic targets more rapidly 3

Fixed-Dose Combinations Available:

• Dapagliflozin-saxagliptin 2
• Empagliflozin-linagliptin 2
• Ertugliflozin-sitagliptin (in development) 2

Safety Profile:

• Low risk of hypoglycemia when used together 4, 5, 9
• No additional safety concerns beyond those of individual agents 4
• SGLT2i-related risks (genital mycotic infections, volume depletion, euglycemic ketoacidosis) remain unchanged 1

Common Pitfalls to Avoid

For SGLT2i:

• Never discontinue SGLT2i solely because glucose-lowering efficacy has declined at lower eGFR—the cardiorenal benefits persist and are the primary reason for continuation 1, 6, 8
• Do not mistake the initial reversible eGFR dip (typically 3-5 mL/min/1.73 m² within weeks of initiation) as a reason to stop therapy 1
• Withhold SGLT2i during prolonged fasting, surgery, or critical illness to reduce ketoacidosis risk 1
• Canagliflozin has been associated with increased amputation risk and bone fractures in some trials, while empagliflozin and dapagliflozin have not shown these signals 8

For DPP4i:

• Do not assume all DPP4i have identical cardiovascular outcome data—while the class is cardiovascular-safe, none have demonstrated significant MACE reduction 5
• DPP4i maintain efficacy in older adults and those with declining renal function, making them preferable to SGLT2i in these populations when glucose lowering is the primary goal 3

For Combination Therapy:

• Do not assume all SGLT2i have identical cardiovascular outcome data—empagliflozin and canagliflozin have the strongest evidence for reducing MACE in patients with established atherosclerotic cardiovascular disease 8
• When combining, prioritize SGLT2i agents with proven kidney or cardiovascular benefits (canagliflozin, dapagliflozin, empagliflozin) 1